Seroatlas · Human Serome Atlas

SLC27A2

Long-chain fatty acid transport protein 2

Also known as: ACSVL1, FACVL1, FATP2, hFACVL1, HsT17226, S27A2_HUMAN, VLACS, VLCS

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
O14975
Gene
SLC27A2
Ensembl
ENSG00000140284
Chromosome
15
Canonical length
620 aa
Protein class
Enzymes, Metabolic proteins, Predicted membrane proteins, Transporters

OverviewNCBI Gene

The protein encoded by this gene is an isozyme of long-chain fatty-acid-coenzyme A ligase family. Although differing in substrate specificity, subcellular localization, and tissue distribution, all isozymes of this family convert free long-chain fatty acids into fatty acyl-CoA esters, and thereby play a key role in lipid biosynthesis and fatty acid degradation. This isozyme activates long-chain, branched-chain and very-long-chain fatty acids containing 22 or more carbons to their CoA derivatives. It is expressed primarily in liver and kidney, and is present in both endoplasmic reticulum and peroxisomes, but not in mitochondria. Its decreased peroxisomal enzyme activity is in part responsible for the biochemical pathology in X-linked adrenoleukodystrophy. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Apr 2009]

Canonical amino-acid sequenceUniProt

620 residues, UniProt reviewed canonical sequence.

>O14975|SLC27A2
     1  MLSAIYTVLA GLLFLPLLVN LCCPYFFQDI GYFLKVAAVG RRVRSYGKRR PARTILRAFL
    61  EKARQTPHKP FLLFRDETLT YAQVDRRSNQ VARALHDHLG LRQGDCVALL MGNEPAYVWL
   121  WLGLVKLGCA MACLNYNIRA KSLLHCFQCC GAKVLLVSPE LQAAVEEILP SLKKDDVSIY
   181  YVSRTSNTDG IDSFLDKVDE VSTEPIPESW RSEVTFSTPA LYIYTSGTTG LPKAAMITHQ
   241  RIWYGTGLTF VSGLKADDVI YITLPFYHSA ALLIGIHGCI VAGATLALRT KFSASQFWDD
   301  CRKYNVTVIQ YIGELLRYLC NSPQKPNDRD HKVRLALGNG LRGDVWRQFV KRFGDICIYE
   361  FYAATEGNIG FMNYARKVGA VGRVNYLQKK IITYDLIKYD VEKDEPVRDE NGYCVRVPKG
   421  EVGLLVCKIT QLTPFNGYAG AKAQTEKKKL RDVFKKGDLY FNSGDLLMVD HENFIYFHDR
   481  VGDTFRWKGE NVATTEVADT VGLVDFVQEV NVYGVHVPDH EGRIGMASIK MKENHEFDGK
   541  KLFQHIADYL PSYARPRFLR IQDTIEITGT FKHRKMTLVE EGFNPAVIKD ALYFLDDTAK
   601  MYVPMTEDIY NAISAKTLKL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SLC27A2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
3
Mean surface accessibility (rSASA)
0.23
Highest tissue expression
269 nTPM

Expression across tissuesHPA

Tissue

  • liver: 269 nTPM
  • kidney: 147 nTPM
  • epididymis: 62 nTPM
  • small intestine: 20 nTPM
  • choroid plexus: 18 nTPM
  • colon: 17 nTPM

Single-cell type

  • cytotrophoblasts: 406 nCPM
  • hepatocytes: 300 nCPM
  • proximal tubule cells: 233 nCPM
  • respiratory ciliated cells: 172 nCPM
  • conjunctival goblet cells: 134 nCPM
  • respiratory secretory cells: 131 nCPM

Immune cell

  • basophil: 64 nTPM
  • NK-cell: 2 nTPM
  • eosinophil: 0.9 nTPM
  • T-reg: 0.9 nTPM
  • gdT-cell: 0.8 nTPM
  • memory CD8 T-cell: 0.8 nTPM

Brain region

  • choroid plexus: 20 nTPM
  • cerebral cortex: 7.6 nTPM
  • hippocampal formation: 5.8 nTPM
  • hypothalamus: 4.9 nTPM
  • basal ganglia: 4.2 nTPM
  • cerebellum: 3.6 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about SLC27A2.

Disease | GeneticClinVar

1 pathogenic / likely-pathogenic of 114 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.97
gnomAD pLI
0
gnomAD missense Z
-0.19
DepMap mean gene effect
-0.08
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of SLC27A2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SLC27A2 as an antibody target. Whether an autoantibody or antibody against SLC27A2 could matter depends on whether native SLC27A2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SLC27A2 is annotated at the cell surface, where native SLC27A2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label SLC27A2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/SLC27A2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...